This Notice of Funding Opportunity (NOFO) invites applications that combine computational and experimental approaches to enable rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in Alzheimer's Disease (AD) and AD-related dementias (ADRD). This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal of this NOFO is to establish robust proof of concept in mouse models or cell-based models of AD/ADRD that will enable rational drug repositioning and the development of precision combination therapies for the treatment and prevention of AD/ADRD.
Application Due Dates: Jun 9, 2025; Oct 6, 2025; Feb 6, 2026; Jun 9, 2026; Oct 6, 2026; Feb 8, 2027; Jun 9, 2027; Oct 8, 2027; Feb 7, 2028
PAR-25-374 Expiration Date May 08, 2028
Application budgets are capped at $1 million in direct costs per year. Application budgets are not limited but need to reflect the actual needs of the proposed project.
The scope of the proposed project should determine the project period. The maximum project period is 5 years.